The use of engineered bacteria as living implants for tissue repair and regeneration in surgical patients with tissue lesions, compared to orthodox post-surgical treatment for enhanced tissue regeneration, infection rate reduction, and other healing benefits?

Abstract

Aim: This review evaluates the effectiveness and protection of engineered microorganisms compared to traditional surgical treatments with a focus on wound healing, contamination price discount, and immune modulation.

Methods: A systematic literature search of the of PubMed, bio material science journal, communication biology and wily advance library databases identified studies published between 2018 and 2024. The overarching studies were preclinical animal trials, early phase human trials, and meta-analyses investigating genetically engineered microorganisms for tissue repair.

The results: Fifteen studies were included: 9 preclinical and 6 early human studies. The engineered microorganism improved wound closure rates by an average of 40% (p < 0.01), improved traction energy, and reduced inflammatory markers by up to 45%. Controlled bacterial lysis minimized harmful effects, with less than 5% of patients experiencing moderate signs and symptoms along with fever or rash. Despite these advantages, challenging situations remain that include optimizing bacterial colonization and addressing long-term

safety.

Conclusion: The engineered microorganism shows great promise as a biocompatible, cost-effective and scalable opportunity for surgical tissue regeneration. Although further studies are needed to overcome safety and regulatory hurdles, this method represents a paradigm shift in regenerative medicine with the potential to improve outcomes for tens of millions worldwide.